Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Institute for Surgical Pathology, University Medical Center, University of Freiburg, Freiburg, Germany.
Cancer Immunol Res. 2020 Apr;8(4):530-543. doi: 10.1158/2326-6066.CIR-19-0513. Epub 2020 Feb 4.
γδ T cells in human solid tumors remain poorly defined. Here, we describe molecular and functional analyses of T-cell receptors (TCR) from tumor-infiltrating γδ T lymphocytes (γδ TIL) that were in direct contact with tumor cells in breast cancer lesions from archival material. We observed that the majority of γδ TILs harbored a proinflammatory phenotype and only a minority associated with the expression of IL17. We characterized TCRγ or TCRδ chains of γδ TILs and observed a higher proportion of Vδ2 T cells compared with other tumor types. By reconstructing matched Vδ2 TCRγ and TCRδ pairs derived from single-cell sequencing, our data suggest that γδ TILs could be active against breast cancer and other tumor types. The reactivity pattern against tumor cells depended on both the TCRγ and TCRδ chains and was independent of additional costimulation through other innate immune receptors. We conclude that γδ TILs can mediate tumor reactivity through their individual γδ TCR pairs and that engineered T cells expressing TCRγ and δ chains derived from γδ TILs display potent antitumor reactivity against different cancer cell types and, thus, may be a valuable tool for engineering immune cells for adoptive cell therapies.
γδ T 细胞在人体实体肿瘤中的特征仍不明确。在这里,我们描述了来自乳腺癌病变中与肿瘤细胞直接接触的肿瘤浸润 γδ T 淋巴细胞 (γδ TIL) 的 T 细胞受体 (TCR) 的分子和功能分析。我们观察到,大多数 γδ TIL 具有促炎表型,只有少数与 IL17 的表达相关。我们对 γδ TIL 的 TCRγ 或 TCRδ 链进行了表征,并观察到与其他肿瘤类型相比,Vδ2 T 细胞的比例更高。通过对来自单细胞测序的匹配 Vδ2 TCRγ 和 TCRδ 对进行重建,我们的数据表明 γδ TIL 可能对乳腺癌和其他肿瘤类型具有活性。针对肿瘤细胞的反应模式取决于 TCRγ 和 TCRδ 链,并且独立于通过其他先天免疫受体进行的额外共刺激。我们得出结论,γδ TIL 可以通过其各自的 γδ TCR 对介导肿瘤反应,并且表达源自 γδ TIL 的 TCRγ 和 δ 链的工程化 T 细胞对不同的癌细胞类型具有强大的抗肿瘤反应性,因此可能是用于过继细胞疗法的免疫细胞工程的有价值的工具。
Cancer Immunol Res. 2020-2-4
Curr Issues Mol Biol. 2021-5-27
Cancer Immunol Immunother. 2024-7-2
Oncotarget. 2017-1-31
Front Immunol. 2020
Med Oncol. 2025-5-19
Curr Oncol. 2025-2-28
Front Immunol. 2024
Front Immunol. 2024-2-15
Front Immunol. 2024-1-11
Front Immunol. 2023